Skip to main content

Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy

Clinical Pharmacokinetics volume 57, pages 739–748 (2018)Cite this article

Abstract

Aim

The aim of this study was to describe the pharmacokinetics of stiripentol in children with Dravet syndrome and to determine the concentrations of stiripentol achieved in this population for the usual 25 mg/kg twice-daily dose.

Methods

Thirty-five children with epilepsy were included in a prospective population pharmacokinetic study (using MONOLIX software). Four blood samples were drawn per patient. Stiripentol area under the plasma concentration–time curve (AUC) values and trough concentrations were simulated for 7000 theoretical children weighing between 10 and 70 kg for the 25 mg/kg twice-daily dose.

Results

The pharmacokinetics of stiripentol was described using a one-compartment model with zero-order absorption and first-order elimination. The apparent clearance (CL/F) and apparent volume of distribution (V d/F) of stiripentol were related to body weight by allometric equations. A dose-dependent non-linearity was also observed with an allometric model relating CL/F to the weight-normalised dose. Mean population estimates (% inter-individual variability) were 4.2 L/h (21%) for CL/F and 82 L (25%) for V d/F. The AUC of stiripentol increased by 300% when body weight increased from 10 to 70 kg.

Conclusion

This population pharmacokinetic model of stiripentol in children with Dravet syndrome confirmed the dose-dependent non-linearity that has been evidenced in adults. It also supported that a 25 mg/kg twice-daily dose might lead to excessive exposure in children >30 kg, suggesting an eventual dose adjustment during adolescence.

Clinical Trial Identifier

This study is part of the STIPOP study (EUDRACT number: 2007-001784-30).

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia. 2011;52(Suppl 2):76–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):72–5.

    Article  PubMed  Google Scholar 

  3. Guerrini R. Epilepsy in children. Lancet Lond Engl. 2006;367:499–524.

    Article  Google Scholar 

  4. Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015;44:104–9.

    Article  PubMed  Google Scholar 

  5. Chiron C, Marchand MC, Tran A, Rey E, d’Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet Lond Engl. 2000;356:1638–42.

    Article  CAS  Google Scholar 

  6. Kassaï B, Chiron C, Augier S, Cucherat M, Rey E, Gueyffier F, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49:343–8.

    Article  PubMed  Google Scholar 

  7. Diacomit. Summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf. Accessed 16 Feb 2017.

  8. Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993;34:305–11.

    Article  PubMed  CAS  Google Scholar 

  9. Perez J, Chiron C, Musial C, Rey E, Blehaut H, d’Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618–26.

    Article  PubMed  CAS  Google Scholar 

  10. Chiron C, Tonnelier S, Rey E, Brunet M-L, Tran A, d’Athis P, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol. 2006;21:496–502.

    Article  PubMed  Google Scholar 

  11. Inoue Y, Ohtsuka Y. STP-1 Study Group. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014;108:725–31.

    Article  PubMed  CAS  Google Scholar 

  12. May TW, Boor R, Mayer T, Jürgens U, Rambeck B, Holert N, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34:390–7.

    Article  PubMed  CAS  Google Scholar 

  13. Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36:661–9.

    Article  PubMed  CAS  Google Scholar 

  14. Peigné S, Rey E, Le Guern M-E, Dulac O, Chiron C, Pons G, et al. Reassessment of stiripentol pharmacokinetics in healthy adult volunteers. Epilepsy Res. 2014;108:909–16.

    Article  PubMed  CAS  Google Scholar 

  15. Ogungbenro K, Aarons L, CRESim & Epi-CRESim Project Groups. A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children. Pharm Res. 2015;32:144–57.

    Article  PubMed  CAS  Google Scholar 

  16. Giraud C, Treluyer J-M, Rey E, Chiron C, Vincent J, Pons G, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos Biol Fate Chem. 2006;34:608–11.

    Article  PubMed  CAS  Google Scholar 

  17. Scott SA, Sangkuhl K, Stein CM, Hulot J-S, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94:317–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal. 2005;49:1020–38.

    Article  Google Scholar 

  19. Lavielle M, Mentré F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn. 2007;34:229–49.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735–50.

    Article  PubMed  CAS  Google Scholar 

  21. Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.

    Article  PubMed  CAS  Google Scholar 

  22. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47:231–43.

    Article  PubMed  CAS  Google Scholar 

  23. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931–56.

    Article  PubMed  CAS  Google Scholar 

  24. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24:67–76.

    Article  PubMed  Google Scholar 

  25. Salem F, Johnson TN, Abduljalil K, Tucker GT, Rostami-Hodjegan A. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet. 2014;53:625–36.

    Article  PubMed  CAS  Google Scholar 

  26. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122–6.

    Article  PubMed  CAS  Google Scholar 

  27. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30:329–32.

    Article  PubMed  CAS  Google Scholar 

  28. Wang C, Peeters MYM, Allegaert K, Blussé van Oud-Alblas HJ, Krekels EHJ, Tibboel D, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012;29:1570–81.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Bertrand J, Comets E, Mentre F. Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters. J Biopharm Stat. 2008;18:1084–102.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036–49.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Verdier M-C, Tribut O, Bentué-Ferrer D. Therapeutic drug monitoring of stiripentol [in French]. Therapie. 2012;67:157–60.

    Article  PubMed  Google Scholar 

  33. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999;9:539–49.

    PubMed  CAS  Google Scholar 

  34. Combes FP, Retout S, Frey N, Mentré F. Powers of the likelihood ratio test and the correlation test using empirical Bayes estimates for various shrinkages in population pharmacokinetics. CPT Pharmacomet Syst Pharmacol. 2014;3:e109.

    Article  CAS  Google Scholar 

  35. Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet. 2014;53:327–46.

    Article  PubMed  CAS  Google Scholar 

  36. Moreland TA, Astoin J, Lepage F, Tombret F, Levy RH, Baillie TA. The metabolic fate of stiripentol in man. Drug Metab Dispos Biol Fate Chem. 1986;14:654–62.

    PubMed  CAS  Google Scholar 

  37. Cloyd JC, Fischer JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther. 1993;53:22–9.

    Article  PubMed  CAS  Google Scholar 

  38. Jullien V, Chhun S, Rey E, Dulac O, Tod M, Chiron C, et al. Pharmacokinetics of clobazam and N-desmethylclobazam in children with Dravet syndrome receiving concomitant stiripentol and valproic acid. Clin Pharmacokinet. 2015;54:527–36.

    Article  PubMed  CAS  Google Scholar 

  39. Yukawa E, Higuchi S, Aoyama T. Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol. 1992;44:755–60.

    Article  PubMed  CAS  Google Scholar 

  40. Yukawa E, Suzuki A, Higuchi S, Aoyama T. Influence of age and co-medication on steady-state carbamazepine serum level-dose ratios in Japanese paediatric patients. J Clin Pharm Ther. 1992;17:65–9.

    Article  PubMed  CAS  Google Scholar 

  41. Banfield CR, Zhu GR, Jen JF, Jensen PK, Schumaker RC, Perhach JL, et al. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Ther Drug Monit. 1996;18:19–29.

    Article  PubMed  CAS  Google Scholar 

  42. Inoue Y, Ohtsuka Y, Oguni H, Tohyama J, Baba H, Fukushima K, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50:2362–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Mireille Cammas (INSERM U1129) for her technical participation in the drug assay.

Author information

Affiliations

  1. INSERM U1129, Paris, France

    Sophie Peigné, Stéphanie Chhun, Elisabeth Rey, Christelle Rodrigues, Catherine Chiron, Gérard Pons & Vincent Jullien

  2. Paris Descartes University, PRES Sorbonne Paris Cité, Paris, France

    Sophie Peigné, Stéphanie Chhun, Elisabeth Rey, Christelle Rodrigues, Catherine Chiron, Gérard Pons & Vincent Jullien

  3. CEA, Gif sur Yvette, France

    Sophie Peigné, Stéphanie Chhun, Elisabeth Rey, Christelle Rodrigues, Catherine Chiron, Gérard Pons & Vincent Jullien

  4. Département de Physiologie-Pharmacologie-Toxicologie, Faculté de Pharmacie, Université Lyon I, Lyon, France

    Michel Tod

  5. Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France

    Michel Tod

  6. Service de Pharmacologie, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015, Paris, France

    Vincent Jullien

  7. Assistance Publique-Hôpitaux de Paris, Paris, France

    Vincent Jullien

Authors
  1. Sophie Peigné
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stéphanie Chhun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Tod
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth Rey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christelle Rodrigues
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Catherine Chiron
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gérard Pons
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vincent Jullien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincent Jullien.

Ethics declarations

Funding

This study was conducted with the financial support of Biocodex.

Conflict of interest

Catherine Chiron and Michel Tod had support from Biocodex for the submitted work and Catherine Chiron was PI of the clinical pharmacokinetic study; Catherine Chiron has received financial support from Biocodex in the previous 3 years. Christelle Rodrigues received a financial support from Biocodex for work not related to this study. Sophie Peigné, Stéphanie Chhun, Elisabeth Rey, Gérard Pons and Vincent Jullien declare no conflicts of interest that might be relevant to this work. The authors have full control of all primary data and agree to allow the journal to review their data if requested.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peigné, S., Chhun, S., Tod, M. et al. Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy. Clin Pharmacokinet 57, 739–748 (2018). https://doi.org/10.1007/s40262-017-0592-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-017-0592-7